Instrument Inactif

Communiqués Opsens Inc. Other OTC

Actions

OPSSF

CA6838231083

Equipement et technologie médicale avancés

Communiqués

12/12/23	HAEMONETICS COMPLETES ACQUISITION OF OPSENS	AQ
08/12/23	OPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS	AQ
01/12/23	OPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS	AQ
28/11/23	OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED	AQ
22/11/23	Opsens : Management’s Discussion & analysis for the year 2023	PU
22/11/23	OPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS	AQ
13/11/23	INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE "FOR" OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATION	AQ
23/10/23	OPSENS ANNOUNCES THE POSITIVE CLINICAL RESULTS FROM THE SAFE-TAVI STUDY WITH SAVVYWIRE IN EUROPE	AQ
17/10/23	OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in San Francisco October 23 - 26, 2023	AQ
13/07/23	OPSENS ANNOUNCES A THIRD CONSECUTIVE QUARTER OF RECORD REVENUES FOR THIRD QUARTER FISCAL 2023	AQ
06/07/23	OPSENS TO HOST THIRD QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY JULY 13, 2023	AQ
06/07/23	Opsens : Interim Consolidated Financial Statements for the nine-month period ended May 31, 2023	PU
10/05/23	OPSENS ANNOUNCES INCLUSION OF SAVVYWIRE™ IN COMPLETE TAVR STUDY	AQ
20/04/23	OpSens Announces Participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference	NE
13/04/23	OPSENS ANNOUNCES RECORD REVENUE FOR SECOND QUARTER FISCAL 2023	AQ
11/04/23	OPSENS ANNOUNCES COMPLETION OF ENROLLMENT IN SAFE-TAVI STUDY WITH SAVVYWIRE® IN EUROPE	AQ
06/04/23	OPSENS TO HOST SECOND QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY APRIL 13, 2023	AQ
05/04/23	OPSENS ANNOUNCES 1,000TH SAVVYWIRE PROCEDURE	AQ
27/03/23	OPSENS APPOINTS JOHN HANNIGAN AS CHIEF FINANCIAL OFFICER	AQ
14/03/23	OPSENS AWARDED INTERVENTIONAL SPECIALTY DIAGNOSTICS AGREEMENT WITH PREMIER FOR SAVVYWIRE™	AQ
28/02/23	OPSENS ANNOUNCES SAVVYWIRE™ USED DURING TWO LIVE CASES AT CRT CONFERENCE	AQ
25/01/23	OpSens Reports Annual General and Special Shareholders Meeting Voting Results	AQ
25/01/23	OPSENS TO PARTICIPATE IN THE LYTHAM PARTNERS INVESTOR SELECT CONFERENCE	AQ
25/01/23	OpSens : to Participate in the Lytham Partners Investor Select Conference, January 31st and February 1st	PU
13/01/23	Opsens : Management’s Discussion & analysis for the 3-month period ended Nov. 30 2022	PU